Pfizer Inc., of New York, said it completed pneumonia case accrual in the CAPiTA (Community-Acquired Pneumonia Immunization Trial in Adults) 65 years and older. The study is designed to test whether Prevnar (pneumococcal polysaccharide conjugate vaccine [13-valent, adsorbed]) is effective in preventing community-acquired pneumonia caused by the 13 pneumococcal serotypes included in the vaccine.

No Comments